This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Sarcoma	Sirtuin 1 (SIRT1); SIRT2	<p>Cell culture and zebrafish studies suggest inhibiting SIRT1 could help treat metastatic Ewing's sarcoma. In tumor samples from patients with Ewing's sarcoma, SIRT1 levels were higher in metastatic tumors than in primary tumors. In a panel of Ewing's sarcoma cell lines, shRNA against <i>SIRT1</i> or a small molecule SIRT1 and SIRT2 inhibitor increased tumor-suppressive NOTCH pathway signaling and decreased viability compared with control shRNA or no treatment. In a zebrafish xenograft model of Ewing's sarcoma, the SIRT1 and SIRT2 inhibitor decreased tumor growth and metastasis compared with vehicle. Next steps could include identifying and evaluating small molecule SIRT1 inhibitors in mouse xenograft models of Ewing's sarcoma.</p> <p>SciBX 7(43); doi:10.1038/scibx.2014.1257 Published online Nov. 6, 2014</p>	Patent and licensing status unavailable	<p>Ban, J. <i>et al. Cancer Res.</i>; published online Oct. 3, 2014; doi:10.1158/0008-5472.CAN-14-1736 Contact: Heinrich Kovar, St. Anna Children's Cancer Research Institute and Medical University Vienna, Vienna, Austria e-mail: heinrich.kovar@ccri.at</p>